2012-09-30 16:18:09 - Recently published research from Datamonitor, "Exelixis, Inc.: Company Analysis", is now available at Fast Market Research

This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.

Scope
* Patient-based forecasts for Exelixis's lead candidate, cabozantinib, supported by key opinion leader research
* Assessment of Exelixis's corporate strategy, operating performance, and earlier-stage pipeline

Highlights

Exelixis's lead candidate is cabozantinib, a an oral inhibitor of the hepatocyte growth factor receptor MET, receptor tyrosine kinase RET, and the vascular endothelial growth factor receptor 2 (VEGFR2). It is currently in Phase III trials for two indications: medullary thyroid cancer and metastatic

castrate-resistant prostate cancer.


Full Report Details at
- www.fastmr.com/prod/464848_exelixis_inc_company_analysis.aspx


For the medullary thyroid cancer (MTC) indication, the US has set a Prescription Drug User Fee Act action date of November 29, 2012 and subsequent launch is expected in 2013 in the US. Datamonitor believes a 2015 launch is likely for the prostate cancer indication in the US.

Reasons to Get this Report
* Assess the potential of cabozantinib based on market size, Phase III results, and future indications
* See how uptake of cabozantinib will drive Exelixis' performance
* Evaluate the company's long-term prospects, based on its plans to expand cabozantinib's potential in further cancer indications

Report Table of Contents:

ABOUT THIS REPORT

* PharmaVitae Explorer database
* Chapter structure

* Sales and product analysis
* Financial analysis

* Data sourcing

* Analyst consensus

EXECUTIVE SUMMARY

* Company introduction

* Recent developments
* Corporate relationships

* Strategic overview
* SWOT analysis

* Strengths
* Weaknesses
* Opportunities
* Threats

SALES AND PRODUCT ANALYSIS

* Sales overview
* Product analysis

* Product sales
* Cabozantinib

* Cabozantinib - medullary thyroid cancer

* Caprelsa was the first therapy to be approved for medullary thyroid cancer
* Nexavar and Sutent are sometimes used off-label in MTC
* Clinical trials
* Factors affecting approval and use
* Key forecasting assumptions

* Cabozantinib - castrate-resistant prostate cancer

* Jevtana and Zytiga are most often used for second- and third-line therapy in metastatic castrate-resistant prostate cancer
* Clinical trials
* Factors affecting approval and use
* Key forecasting assumptions
* Cabozantinib trials in other indications

* Other products

FINANCIAL ANALYSIS

* Financial performance overview

* Operating costs and profit analysis, 2006-11
* Operating costs and profit analysis, 2012-17

APPENDIX

* References
* Exchange rates

TABLES

* Table: Key Exelixis corporate relationships
* Table: Exelixis key product sales, by region ($m), 2012-17
* Table: Exelixis Phase III trials in medullary thyroid cancer
* Table: Cabozantinib US sales forecast model, 2013-17
* Table: Cabozantinib EU sales forecast model, 2013-17
* Table: Cabozantinib US sales forecast model, 2015-17
* Table: Exelixis operating revenue/cost analysis ($m), 2006-11
* Table: Exelixis operating revenue/cost analysis ($m), 2012-17
* Table: Exchange rates, 2012

FIGURES

* Figure: PharmaVitae Explorer
* Figure: Exelixis prescription pharmaceutical performance, sales ($m) and growth rate 2012-17
* Figure: Exelixis key product sales ($m), 2012-17
* Figure: Exelixis operating revenue/cost analysis ($m), 2006-17

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.